Rani Therapeutics(RANI)

SAN JOSE, CABiotechnology3 H-1B visas (FY2023)

Focus: Rani Therapeutics is a public biotech company developing a proprietary oral delivery platform (RaniPill) to enable non-invasive administration of biologics, currently focused on metabolic diseases including obesity.

Metabolic Diseases

Profile data last refreshed 12h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Rani Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Rani Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$1M

FY2025

Pipeline & Clinical Trials

Mock-RP

Not Determined

N/A

Clinical Trials (1)

NCT04911296Pill Swallow Study

N/A

Help build intelligence for Rani Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering oral biologics delivery platform addresses a massive unmet need in drug administration, offering technical differentiation in an emerging category.
Public company status provides equity liquidity and access to capital markets, reducing failure risk relative to private-stage biotech.
Early-stage pipeline (Phase 1) in obesity treatment positions you at the frontier of a high-value therapeutic area with significant commercial upside.

Watch Out For

Extreme cash burn relative to revenue ($27M R&D spend vs. $1M revenue in FY2025) and only $4M cash position signals imminent financing pressure or restructuring within 12–18 months.
Zero revenue-generating products, no Phase 2+ programs, and only 5 total trials indicate clinical validation is still years away; significant execution risk on platform viability.
0 active job openings and no hiring by department data suggest frozen or minimal headcount expansion, limiting growth opportunities for new hires.

Generated by Claude from Rani Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

RT-102

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05164614Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

Phase 1

RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

Obesity

PHASE_1

Clinical Trials (1)

NCT06891287An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

Phase 1

Stelara

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05890118Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

Phase 1

RaniPill capsule containing octreotide

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT03798912A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Metabolic Diseases

H-1B (2023): 3 approvals

Publications: 5 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Metabolic Diseases

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$1M

R&D Spend

$27M(2596%)33%

Net Income

-$30M

Cash

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(5)

Recent peer-reviewed publications with author affiliations at this company

Oral delivery of an ustekinumab biosimilar with bioavailability comparable to subcutaneous administration in healthy human participants.

European journal of clinical pharmacology

2026

PMID:41553505

An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study.

British journal of clinical pharmacology

2025

PMID:40194767

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Rani Therapeutics(RANI)

About Rani Therapeutics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Rani Therapeutics(10)

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship

Research Publications(5)